Telehealth & Digital Health

A new financial deal shines a light on Modeyso, a breakthrough therapy for a rare pediatric brain cancer, linking Wall Street to life-saving innovation.

An essay contest for medical trainees aims to fix a critical gap in patient care, using frontline stories to reshape how doctors learn about nutrition.

With the hire of world-renowned surgeon Dr. Nelson Oyesiku, Piedmont Healthcare signals its ambition to become a top destination for neurological care in the Southeast.

The arrival of South Africa's first generic hormonal IUD aims to tackle high costs and low uptake of long-acting contraception in a nation of high unplanned pregnancies.

A $500K grant accelerates a novel therapy that dismantles tumor defenses, offering new hope for patients with hard-to-treat gastroesophageal cancers.

With a seasoned dealmaker at the helm, Elkedonia is advancing a first-in-class, non-hallucinogenic drug for depression targeting a novel protein.

Obsidian Therapeutics will unveil pivotal Phase 2 data on OBX-115, an engineered cell therapy that may offer a safer, more potent weapon against melanoma.

California's largest school insurance pool is rolling out a virtual autoimmune care program to thousands, aiming to cut costs and improve teacher health.

A new AI-driven platform moves beyond static reports, offering continuous genomic updates to give cancer patients access to the latest treatment options.

A 3-year study of COVID survivors reveals a startling new risk: late-onset cognitive impairment, pushing for a radical shift in long-term brain monitoring.

A new alliance between UltraGreen and LifeSignals will bring advanced wearable heart monitors to a global market, tackling rising cardiovascular disease.

Upcoming Phase 1 data for ABCL635 could validate a novel antibody approach for hot flashes, challenging the market and offering new hope for millions.

Spurred by celebrity stories and a viral campaign, the Webby-winning Know Your Lemons app offers personalized risk scores and private screening plans.

Astellas and Pfizer's PADCEV-Keytruda combo, showing a 47% drop in recurrence risk, earns FDA Priority Review, offering new hope for bladder cancer patients.

A new gene therapy that reprograms cancer cells into immune activators shows major promise, blending personalized treatment with off-the-shelf convenience.

Interim study results suggest a common food product may significantly enhance the effectiveness of modern cancer treatments, heralding a new era of care.

A new partnership between Wilcrest Pharma and healthcare giant Premier, Inc. aims to streamline hazardous drug compounding for thousands of U.S. hospitals.

Byondis presents two novel ADC platforms at AACR 2026, aiming to solve drug resistance and offer hope for patients unresponsive to immunotherapy.

With $36M secured, Orthogon Therapeutics is advancing a first-in-class oral drug for BK virus, offering a new lifeline for transplant patients.

On World Hemophilia Day, experts reveal over 75% of people with bleeding disorders are undiagnosed, facing a life of pain without access to basic care.